◎ Sugi Atlas

Atlas / Drug / Pertuzumab

Pertuzumab

drug
On this page

Also known as OmnitargOmnitarg perjetaPerjetaPertuzumab component of phesgoPertuzumab-zzxfRG-1273RHUMAB 2C4RHUMAB-2C4RHUMAB2C4SYSA-1901Sysa-1901 (pertuzumab biosimilar)Sysa1901

Summary

Pertuzumab (CHEMBL2007641) is an approved antibody (ATC L01FD02) targeting ERBB2; indicated across 27 conditions including breast carcinoma and breast neoplasm; with CIViC clinical evidence for 22 variant-indication associations (e.g. ERBB2 Amplification in colorectal cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FD02
  • Targets: 1 (ERBB2)
  • Indications: 27 conditions
  • Clinical trials: 263
  • Precision-oncology evidence (CIViC): 22 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2007641
NamePertuzumab
TypeAntibody
Max phase4
ATCL01FD02

Also known as: Omnitarg, Omnitarg perjeta, Perjeta, Pertuzumab, Pertuzumab component of phesgo, Pertuzumab-zzxf, RG-1273, RHUMAB 2C4, RHUMAB-2C4, RHUMAB2C4, SYSA-1901, Sysa-1901 (pertuzumab biosimilar)

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ERBB2erb-b2 receptor tyrosine kinase 2Inhibition817.7%P04626

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): ERBB2.

Top Reactome pathways

33 total, by targets touching each:

PathwayTargetsGenes
Signaling by ERBB21ERBB2
SHC1 events in ERBB2 signaling1ERBB2
PLCG1 events in ERBB2 signaling1ERBB2
PIP3 activates AKT signaling1ERBB2
GRB7 events in ERBB2 signaling1ERBB2
Downregulation of ERBB2:ERBB3 signaling1ERBB2
GRB2 events in ERBB2 signaling1ERBB2
PI3K events in ERBB2 signaling1ERBB2
Constitutive Signaling by Aberrant PI3K in Cancer1ERBB2
Sema4D induced cell migration and growth-cone collapse1ERBB2
RAF/MAP kinase cascade1ERBB2
ERBB2 Regulates Cell Motility1ERBB2
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling1ERBB2
ERBB2 Activates PTK6 Signaling1ERBB2
Downregulation of ERBB2 signaling1ERBB2
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors1ERBB2
Constitutive Signaling by Overexpressed ERBB21ERBB2
Drug-mediated inhibition of ERBB2 signaling1ERBB2
Signaling by ERBB2 KD Mutants1ERBB2
Resistance of ERBB2 KD mutants to trastuzumab1ERBB2
Resistance of ERBB2 KD mutants to sapitinib1ERBB2
Resistance of ERBB2 KD mutants to tesevatinib1ERBB2
Resistance of ERBB2 KD mutants to neratinib1ERBB2
Resistance of ERBB2 KD mutants to osimertinib1ERBB2
Resistance of ERBB2 KD mutants to afatinib1ERBB2
Resistance of ERBB2 KD mutants to AEE7881ERBB2
Resistance of ERBB2 KD mutants to lapatinib1ERBB2
Signaling by ERBB2 ECD mutants1ERBB2
Signaling by ERBB2 TMD/JMD mutants1ERBB2
Drug resistance in ERBB2 TMD/JMD mutants1ERBB2

Dominant GO biological processes

GO termTargets
protein phosphorylation1
signal transduction1
cell surface receptor signaling pathway1
enzyme-linked receptor protein signaling pathway1
cell surface receptor protein tyrosine kinase signaling pathway1
epidermal growth factor receptor signaling pathway1
heart development1
neuromuscular junction development1
motor neuron axon guidance1
cell population proliferation1
Schwann cell development1
peptidyl-tyrosine phosphorylation1
neuron differentiation1
positive regulation of cell growth1
regulation of microtubule-based process1

Indications & clinical

Indications

27 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
breast carcinoma4MONDO:0004989EFO:0000305
breast neoplasm4MONDO:0021100EFO:0003869
neoplasm4MONDO:0005070EFO:0000616
HER2 positive breast carcinoma4MONDO:0006244EFO:1000294
carcinoma of esophagus3MONDO:0019086EFO:0002916
inflammatory breast carcinoma3MONDO:0006804EFO:1000984
gastric neoplasm3MONDO:0021085MONDO:0001056
ovarian cancer3MONDO:0008170MONDO:0008170
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
colorectal adenocarcinoma2MONDO:0005008EFO:0000365
angiosarcoma2MONDO:0016982EFO:0003968
peritoneal neoplasm2MONDO:0006901MONDO:0002087
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
lymphoid neoplasm2MONDO:0005157EFO:0001642
prostate carcinoma2MONDO:0005159EFO:0001663
colorectal neoplasm2MONDO:0005335MONDO:0005575
male breast carcinoma1MONDO:0005628EFO:0006861
rectal cancer1MONDO:0006519EFO:1000657
colonic neoplasm1MONDO:0005401MONDO:0021063
breast disorder1MONDO:0002657EFO:0009483

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 263.

Phase distribution

PhaseTrials
PHASE2129
PHASE360
PHASE123
PHASE1/PHASE222
Not specified14
PHASE2/PHASE37
PHASE46
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05420454PHASE4RECRUITINGA Study for the Neoadjuvant Treatment of Breast Cancer
NCT05420467PHASE4RECRUITINGA Study for the Adjuvant Treatment of Breast Cancer
NCT07093931PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
NCT01501487PHASE4COMPLETEDMINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
NCT02445586PHASE4COMPLETEDSafety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
NCT05036005PHASE4UNKNOWNNeoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
NCT01996267PHASE3ACTIVE_NOT_RECRUITINGNeoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
NCT02320435PHASE3ACTIVE_NOT_RECRUITINGA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
NCT02344472PHASE3ACTIVE_NOT_RECRUITINGDetect V / CHEVENDO (Chemo vs. Endo)
NCT02568839PHASE2/PHASE3ACTIVE_NOT_RECRUITINGNeoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
NCT02625441PHASE3ACTIVE_NOT_RECRUITINGAdjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer
NCT02947685PHASE3ACTIVE_NOT_RECRUITINGRandomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT03595592PHASE3ACTIVE_NOT_RECRUITINGNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03803553PHASE3RECRUITINGIdentification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT04193059PHASE3ACTIVE_NOT_RECRUITINGStudy Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
NCT04208178PHASE3ACTIVE_NOT_RECRUITINGStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
NCT04514419PHASE3ACTIVE_NOT_RECRUITINGTreatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
NCT04784715PHASE3ACTIVE_NOT_RECRUITINGTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT05113251PHASE3ACTIVE_NOT_RECRUITINGTrastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05132582PHASE3ACTIVE_NOT_RECRUITINGA Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05188313PHASE3RECRUITINGTRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
NCT05256225PHASE3RECRUITINGTesting the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05426486PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
NCT05760612PHASE3RECRUITINGAdjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
NCT05786716PHASE2/PHASE3RECRUITINGDETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT05802225PHASE3ACTIVE_NOT_RECRUITINGClinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
NCT05838066PHASE3RECRUITINGEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
NCT05883852PHASE3RECRUITINGEC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
NCT06278870PHASE3RECRUITINGDisitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
NCT06490536PHASE3RECRUITINGThe Sagittarius Trial
NCT06747338PHASE3RECRUITINGA Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
NCT06876714PHASE3RECRUITINGShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
NCT06891833PHASE2/PHASE3RECRUITINGA Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
NCT07003074PHASE3RECRUITINGA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07057427PHASE3RECRUITINGEfficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
NCT07196774PHASE3RECRUITINGA Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
NCT07294508PHASE2/PHASE3RECRUITINGA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
NCT07294534PHASE2/PHASE3NOT_YET_RECRUITINGA Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
NCT07377643PHASE3RECRUITINGIBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
NCT07441460PHASE3RECRUITINGA Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Clinical evidence (CIViC)

Variant × indication × effect (22 predictive associations from 24 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
ERBB2 AmplificationColorectal CancerSensitivity/ResponsePertuzumab + TrastuzumabCIViC BEID11668 +2
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponseTrastuzumab + Docetaxel + PertuzumabCIViC BEID1077
ERBB2 AmplificationCancerSensitivity/ResponseTrastuzumab + PertuzumabCIViC BEID12025
ERBB2 AmplificationHer2-receptor Positive Breast CancerSensitivity/ResponsePertuzumab + Trastuzumab + DocetaxelCIViC BEID1437
ERBB2 AmplificationBladder CarcinomaSensitivity/ResponseTrastuzumab + PertuzumabCIViC BEID5982
ERBB2 AmplificationBiliary Tract CancerSensitivity/ResponsePertuzumab + TrastuzumabCIViC BEID5983
ERBB2 AmplificationSalivary Gland CarcinomaSensitivity/ResponsePertuzumab + TrastuzumabCIViC BEID5984
ERBB2 AmplificationPancreatic CancerSensitivity/ResponseTrastuzumab + PertuzumabCIViC BEID5985
ERBB2 AmplificationUterine CancerSensitivity/ResponseTrastuzumab + PertuzumabCIViC BEID5986
ERBB2 MutationLung Non-small Cell CarcinomaSensitivity/ResponsePertuzumab + TrastuzumabCIViC BEID5980
ERBB2 Mutation OR ERBB3 MutationColorectal CancerSensitivity/ResponseTrastuzumab + PertuzumabCIViC BEID11669
BRAF V600EAnaplastic Thyroid CarcinomaSensitivity/ResponsePertuzumab + VemurafenibCIViC CEID5961
ERBB2 AmplificationCholangiocarcinomaSensitivity/ResponsePertuzumab + TrastuzumabCIViC CEID7638
NRG1 FusionPancreatic AdenocarcinomaSensitivity/ResponseErlotinib + PertuzumabCIViC CEID7534
ERBB3 A232VCancerSensitivity/ResponseLapatinib + Duligotuzumab + Trastuzumab + PertuzumabCIViC DEID9630
ERBB3 EXPRESSIONMelanomaSensitivity/ResponsePertuzumabCIViC DEID3051
ERBB3 EXPRESSIONPancreatic Ductal AdenocarcinomaSensitivity/Response9F7-F11 + PertuzumabCIViC DEID865
ERBB3 G284RCancerSensitivity/ResponseDuligotuzumab + Trastuzumab + Pertuzumab + LapatinibCIViC DEID9684
ERBB3 OverexpressionLung Non-small Cell CarcinomaSensitivity/ResponsePertuzumabCIViC DEID7804
ERBB3 P262HCancerSensitivity/ResponsePertuzumab + Duligotuzumab + Trastuzumab + LapatinibCIViC DEID9673
ERBB3 V104MCancerSensitivity/ResponsePertuzumab + Trastuzumab + Lapatinib + DuligotuzumabCIViC DEID9670
ERBB3 V855ALung Non-small Cell CarcinomaSensitivity/ResponseAfatinib + PertuzumabCIViC DEID1845

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

86 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
AFATINIBChEMBL + PubChemPhase 4 (approved)ERBB2
DACOMITINIBChEMBL + PubChemPhase 4 (approved)ERBB2
GEFITINIBChEMBL + PubChemPhase 4 (approved)ERBB2
LAPATINIB DITOSYLATEChEMBL + PubChemPhase 4 (approved)ERBB2
LAZERTINIBChEMBL + PubChemPhase 4 (approved)ERBB2
MOBOCERTINIBChEMBL + PubChemPhase 4 (approved)ERBB2
ACALABRUTINIBChEMBLPhase 4 (approved)ERBB2
AFATINIB DIMALEATEChEMBLPhase 4 (approved)ERBB2
AMIODARONEChEMBLPhase 4 (approved)ERBB2
ASTEMIZOLEChEMBLPhase 4 (approved)ERBB2
BITHIONOLChEMBLPhase 4 (approved)ERBB2
BOSUTINIBChEMBLPhase 4 (approved)ERBB2
BRIGATINIBChEMBLPhase 4 (approved)ERBB2
CABOZANTINIBChEMBLPhase 4 (approved)ERBB2
CHLORPROMAZINEChEMBLPhase 4 (approved)ERBB2
CLOTRIMAZOLEChEMBLPhase 4 (approved)ERBB2
COLISTINChEMBLPhase 4 (approved)ERBB2
DASATINIBChEMBLPhase 4 (approved)ERBB2
DOXORUBICINChEMBLPhase 4 (approved)ERBB2
EBASTINEChEMBLPhase 4 (approved)ERBB2
ECONAZOLEChEMBLPhase 4 (approved)ERBB2
ERLOTINIBChEMBLPhase 4 (approved)ERBB2
FLUPHENAZINEChEMBLPhase 4 (approved)ERBB2
HEXACHLOROPHENEChEMBLPhase 4 (approved)ERBB2
IBRUTINIBChEMBLPhase 4 (approved)ERBB2
IMATINIBChEMBLPhase 4 (approved)ERBB2
LAPATINIBChEMBLPhase 4 (approved)ERBB2
MICONAZOLEChEMBLPhase 4 (approved)ERBB2
MITOXANTRONEChEMBLPhase 4 (approved)ERBB2
NERATINIBChEMBLPhase 4 (approved)ERBB2
OSIMERTINIBChEMBLPhase 4 (approved)ERBB2
PACLITAXELChEMBLPhase 4 (approved)ERBB2
PONATINIBChEMBLPhase 4 (approved)ERBB2
SORAFENIBChEMBLPhase 4 (approved)ERBB2
TAMOXIFENChEMBLPhase 4 (approved)ERBB2
TIRABRUTINIBChEMBLPhase 4 (approved)ERBB2
TRIBROMSALANChEMBLPhase 4 (approved)ERBB2
TUCATINIBChEMBLPhase 4 (approved)ERBB2
VANDETANIBChEMBLPhase 4 (approved)ERBB2
ZANUBRUTINIBChEMBLPhase 4 (approved)ERBB2
ALISERTIBChEMBLPhase 3ERBB2
ALVOCIDIBChEMBLPhase 3ERBB2
CANDESARTANChEMBLPhase 3ERBB2
CANERTINIBChEMBLPhase 3ERBB2
CEDIRANIBChEMBLPhase 3ERBB2
ENCLOMIPHENEChEMBLPhase 3ERBB2
MASITINIBChEMBLPhase 3ERBB2
POZIOTINIBChEMBLPhase 3ERBB2
PYROTINIBChEMBLPhase 3ERBB2
REMIBRUTINIBChEMBLPhase 3ERBB2
TANESPIMYCINChEMBLPhase 3ERBB2
ZONGERTINIBChEMBLPhase 3ERBB2
AEE-788ChEMBLPhase 2ERBB2
ALLITINIBChEMBLPhase 2ERBB2
ATUZABRUTINIBChEMBLPhase 2ERBB2
BENZETHONIUM CHLORIDEChEMBLPhase 2ERBB2
CENISERTIBChEMBLPhase 2ERBB2
CLOSANTELChEMBLPhase 2ERBB2
CP-724714ChEMBLPhase 2ERBB2
DEFOSBARASERTIBChEMBLPhase 2ERBB2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot